Search
News & Events
'Natural killers' potential new cancer weaponThe Cancer Immunology team at The Kids is investigating how the body's 'natural killer' cells can be harnessed to fight cancer – whilst also protecting kids from nasty chemotherapy side effects.
News & Events
Finding new treatments for rare brain cancers in infantsThe WA Kids Cancer Centre has secured $1.1 million in funding from the Medical Research Future Fund’s (MRFF) Paediatric Brain Cancer Research Stream 2 to develop more effective and less toxic treatments for rare brain cancers in infants.
News & Events
Lab results confirm promise of new immunotherapy gel for kids cancerNewly published research from The Kids Research Institute Australia and The University of Western Australia has found a gel applied during surgery to treat sarcoma tumours is both safe and highly effective at preventing the cancer from growing back.
News & Events
Why timing matters: How tumours respond to immunotherapy treatments over timeResearchers have identified key differences between cancers that respond to immunotherapy and those that do not.
News & Events
Researchers narrow down field of new treatments for most common childhood brain cancerCancer researchers have narrowed-down the field of immunotherapy drugs which could be used to tackle a form of childhood brain cancer.
News & Events
The Kids Cancer Researcher wins prestigious Cancer Council WA awardThe Kids Research Institute Australia cancer researcher, Dr Jason Waithman, has been named Cancer Council WA’s 2021 Cancer Researcher of the Year.
News & Events
WA Kids Cancer Centre researchers appointed to Brain Cancer Expert Advisory PanelDr Jessica Buck and Associate Professor Raelene Endersby have been appointed to the prestigious Australian Brain Cancer Mission Expert Advisory Panel.
Research
Long-term outcomes of symptomatic optic pathway glioma: 32-year experience at a single Western Australian tertiary pediatric oncology centerOptic pathway gliomas (OPGs) are associated with significant risk of visual and endocrine morbidity, but data on long-term outcomes in symptomatic patients is sparse. This study reviews the clinical course, disease progression, survival outcomes and long-term sequelae in pediatric patients with symptomatic OPGs in our institution over three decades.
Research
A multi-institutional retrospective pooled outcome analysis of molecularly annotated pediatric supratentorial ZFTA-fused ependymomaZFTA-RELA (formerly known as c11orf-RELA) fused supratentorial ependymoma has been recognized as a novel entity in the 2016 WHO classification of CNS tumors and further defined in the recent 2021 edition.
Research
Identification of fatty acid amide hydrolase as a metastasis suppressor in breast cancerClinical management of breast cancer (BC) metastasis remains an unmet need as it accounts for 90% of BC-associated mortality. Although the luminal subtype, which represents >70% of BC cases, is generally associated with a favorable outcome, it is susceptible to metastatic relapse as late as 15 years after treatment discontinuation.